MiRXES

MiRXES is a Singapore-headquartered biotech firm with R&D, manufacturing, and clinical lab operations in Singapore, USA, Japan, and China. A molecular diagnostics company, it specialises in microRNA technologies and the development, manufacturing, and provision of diagnostic test kits and clinical services.
MiRXES offers blood tests which use microRNAs - small strands of genetic code found in the bloodstream - as cancer markers. Blood-based microRNAs have, within their genetic code, information about the cancer profiles they carry and therefore have potential to work as a signaller for the presence of different types of cancer.
In February, MiRXES won the rights to manufacture and commercialise the Sars-CoV-2 diagnostic test kits for the novel coronavirus COVID-19. The diagnostic test kit was developed by Singapore's and Tan Tock Seng Hospital, and has received provisional authorisation from the Health Sciences Authority.
MiRXES is backed by Singapore-based venture capital firm Venturecraft, which invests in global growth-stage and late-stage ventures in medtech, biotech, and digital health.

Main Menu

See Also

Main Menu